- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
EyeCon 2022: Management options for the treatment of pediatric myopia
Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.
This transcript has been edited for clarity:
My name is Dr. Jefferson Doyle. I'm an assistant professor of ophthalmology and genetics at the Wilmer Eye Institute at Johns Hopkins University.
My talk today is going to cover the current literature discussing management options for the treatment of pediatric myopia. Broadly speaking, this is going to cover public health measures, including time outdoors. It's going to cover pharmacological approaches including the current atropine data that has been completed, and the ongoing studies that are upcoming. We will discuss optical measures. Also orthokeratology is something that's been around for a long time.
More recently, there's been actually contact lens data, looking at dual-focus lenses, as well as most recently, actually, glasses data, again, discussing a dual-focus approach that appears to be very promising.
We'll also discuss the data that actually covers combined approaches, which is somewhat limited at the moment, but there is some out there. Each of these topics will actually we will go over the current challenges that exist, the limitations in where the data is at this moment, and what we hope can be achieved in the future.
